Locally advanced rectal cancer: Qualitative and quantitative evaluation of diffusion-weighted MR imaging in the response assessment after neoadjuvant chemo-radiotherapy

Pietro Valerio Foti a,∗, Giuseppe Privitera a, Sebastiano Piana a, Stefano Palmucci a, Corrado Sapatola a, Roberta Bevilacqua a, Luigi Raffaele a, Vincenzo Salamone a, Rosario Caltabiano b, Gaetano Magro b, Giovanni Li Destri c, Pietro Milone a, Giovanni Carlo Ettorre a

a Radiodiagnostic and Radiotherapy Unit, University Hospital “Policlinico-Vittorio Emanuele”, Catania, Italy
b Department G.F. Inggrassia—Institute of Pathology, University of Catania, Catania, Italy
c Department G.F. Inggrassia—Unità Operativa Chirurgia Digerente Colorettale, University of Catania, Catania, Italy

A R T I C L E   I N F O

Article history:
Received 3 May 2016
Received in revised form 29 June 2016
Accepted 29 June 2016
Available online 18 July 2016

Keywords:
Chemoradiation
Magnetic resonance imaging
Diffusion-weighted imaging
Rectal cancer
Treatment response
Staging

A B S T R A C T

Purpose: to investigate the added value of qualitative and quantitative evaluation of diffusion weighted (DW) magnetic resonance (MR) imaging in response assessment after neoadjuvant chemo-radiotherapy (CRT) in patients with locally advanced rectal cancer (LARC).

Methods: 31 patients with LARC (stage ≥ T3) were enrolled in the study. All patients underwent conventional MRI and DWI before starting therapy and after neoadjuvant CRT. All patients underwent surgery; pathologic staging represented the reference standard. For qualitative analysis, two radiologists retrospectively reviewed conventional MR images and the combined set of conventional and DW MR images and recorded their confidence level with respect to complete response (ypCR). For quantitative analysis, tumor’s apparent diffusion coefficient (ADC) values were measured at each examination. ADC pre-CRT, ADC post-CRT and ∆ADC post−ADC pre of the three groups of response (ypCR, partial response ypPR, stable disease ypSD) were compared. Receiver−operating characteristics (ROC) curve analysis was employed to investigate the discriminatory capability for ypCR responders (ypCR, ypPR) and ypSD of each measure.

Results: addition of DWI to conventional T2-weighted sequences improved diagnostic performance of MRI in the evaluation of ypCR. A low tumor ADC value in the pre-CRT examination, a high ADC value in the post-CRT examination, a high ∆ ADC post−ADC pre [>0.3 (×10−3 mm2/s)] were predictive of ypCR.

Conclusions: DW sequences improve MR capability to evaluate tumor response to CRT. Nevertheless, no functional MR technique alone seems accurate enough to safely select patients with ypCR.

© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Rectal cancer is one of the most frequent neoplasias, with an incidence of 40 in 100,000 [1]. Over the last two decades its treatment has undergone many changes and innovation, thus more precise preoperative evaluation lead to refined patient selection for appropriate treatment strategies. The tumor stage determines whether radiation and chemotherapy should be used in addition to surgery. In particular, T1–T2 N0 tumors are managed surgically, without neoadjuvant treatment whereas neoadjuvant chemo-radiotherapy (CRT) followed by total mesorectal excision (TME) surgery represents the standard treatment for locally advanced rectal carcinoma (≥T3; any T, N+) [2].

According to literature data 15–27% of the patients treated with CRT achieve a pathological complete response (ypCR), a partial response is seen in 54–75% and others show no response at all [3].

In view of these advances of CRT, alternative approaches to radical surgery have been proposed. Therefore, staging rectal cancer before and after CRT and assessing tumor response have become a very critical issue and imaging studies play a key role with relevant implications in patients’ management.

On one hand response assessment during CRT could possibly re-orientate non-responding patients to a different treatment
modality (e.g. early surgery) or to treatment intensification (e.g. dose escalation or addition of targeted agents); on the other hand response assessment before surgery may enable physicians to offer patients who achieve a clinical complete response less extensive surgery, such as sphincter-saving local excision [4], or even a ‘wait-and-see’ policy [5,6].

According to the European guidelines, magnetic resonance (MR) imaging is the most accurate technique for predicting tumor stage [5,7]. Nevertheless, MRI, as a morphologic imaging modality, has inherent limitations in the differentiation of residual viable tumor from diffuse fibrotic change; therefore, conventional MRI sequences cannot be used to predict complete response to CRT [8,9].

The reported overall accuracy of MRI in predicting the pathologic stage of nonirradiated rectal cancer is 71–91% (mean 85%) for T staging and 43–85% (75%) for N staging; on the other hand the reported overall accuracy of MRI in predicting the pathologic stage of irradiated rectal cancer is 47–54% (50%) for T staging and 64–68% (65%) for N staging [7,10].

Since conventional MR sequences are insufficient for reliably assessing these critical issues there is considerable enthusiasm for employing functional imaging techniques such as diffusion-weighted (DW) MR imaging [11], which may depict microstructural and metabolic treatment-induced changes of the tumor before morphological changes become apparent. DWI allows to perform quantitative measures such as apparent diffusion coefficient (ADC); it may be used as a noninvasive imaging biomarker of tumor aggressiveness [12,13] and to monitor and predict tumor response to CRT [14].

In recent years different imaging tools either volumetric (tumor volume reduction rate [15], magnetic resonance volumetry [16]) or functional [6] have been investigated as potential imaging-based biomarker of treatment response; in particular, the role of qualitative and quantitative DWI findings for prediction of tumor response to CRT has been evaluated.

Kim et al. [8] demonstrated that in patients with locally advanced rectal cancer, adding DW MR imaging to conventional MR imaging yields better diagnostic accuracy than use of conventional MR imaging alone in the evaluation of complete response to neoadjuvant CRT.

Other studies [6] have investigated the role of ADC measurements (potential markers of response being pre-CRT, post-CRT ADC measures and ΔADC) for prediction of treatment outcome and for early detection of tumor response in patients with locally advanced rectal cancer. Sometimes, however the obtained results are discordant and DWI seems not accurate enough to safely select patients for organ preservation.

The aims of our study were:

- to investigate the added value of qualitative DW MRI evaluation in the response assessment after neoadjuvant CRT in patients with locally advanced rectal cancer;
- to evaluate the diagnostic performance of rectal cancer’s ADC measurements, the quantitative parameter of diffusion, for the assessment of therapeutic response to CRT.

2. Materials and methods

2.1. Patients

This was a single institution retrospective cohort study. The work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans and in accordance with recommendations of the local ethic committee. Informed consent was waived due to the retrospective study design.

Between October 2011 and May 2015, 47 patients with diagnosis of rectal cancer were considered for eligibility.

Inclusion criteria were as follows: histologically proven rectal carcinoma, staged on rectal MRI with DWT3–4 and/or with positive regional lymph-node, neoadjuvant CRT, post-CRT rectal MRI with DWI, subsequent surgery.

Exclusion criteria were: previous CRT for primary rectal carcinoma or tumor in other organ (n = 1); contraindication to MR imaging examination (n = 2); delayed (more than 8 months after CRT), cancelled surgery or surgery performed in other institution (n = 2); insufficient quality of MR examination (e.g. owing to metal implants or movement artifacts) (n = 2); distant metastases (n = 4); lack of follow-up MR examination (n = 5).

All patients underwent a staging protocol before preoperative CRT, that included: digital rectal examination, complete blood tests, colonoscopy, contrast enhanced computed tomography (CT) of the chest and the abdomen, external pelvic phased-array MR examination and transrectal ultrasound.

2.2. Reference standard

Pretreatment stage (cT cN) was compared with pathologic stage (ypT ypN). Pathologic staging represented the reference standard and was based on the TNM staging system (VII ed.).

The response was graded as follows. No response to treatment was defined as stable disease (ypSD). A partial response (ypPR) to treatment was defined as downstaging, or reduction of at least one level in T or N staging between the baseline MR exam and histopathological staging. Pathological complete response (ypCR) was defined as the absence of any residual tumor cells detected in the operative specimen (ypTO ypN0).

2.3. Neoadjuvant CRT treatment plan

CRT was performed by means of integration between an initial induction chemotherapy (ICT) and a subsequent concurrent radiochemotherapy (CRCT), over a period of 9 weeks.

During the ICT phase, all patients received a FOLFOX 4 chemotherapy schedule for two cycles, with Oxaliplatin 85 mg/m² in 3 h i.v. infusion (on day 1), 5-Fluoruracil 400 mg/m² i.v. bolus, Folinic acid 200 mg/m², 5-Fluoruracil 600 mg/m² continuous intravenous infusion over 22 h (on day 1 and 2). The cycle was repeated after 14 days, by previous clinical and haematological examination.

A CT radiotherapy simulation was conducted during the ICT phase, in order to prepare the treatment plan.

The CRCT phase requires a continuous i.v. infusion of 5-Fluoruracil at 250 mg/m² daily during all radiotherapy treatment period. Radiation therapy was conducted with patient in prone position, by means of a belly board position system, in order to reduce the dose to the small bowel.

Radiotherapy was planned using a 3D-Conformal technique (Fig. 1), to ensure a coverage of the whole pelvis, including rectum, mesorectum, common iliac, internal and external iliac lymph nodes, obturator lymph nodes. This volume was defined as CTV 1 (Clinical Target Volume 1) and was irradiated to a dose of 45 Gy, with a conventional fractionation of 1.8 Gy/day. A second volume, called CTV2, was also defined to give a boost to the site of the primary tumor in the rectum, by means of a concomitant irradiation during the last six fractions, after an interval of 6 h from the first fraction. This volume received a dose of 9 Gy, with a fractionation of 1.5 Gy/day.

Using the above described concomitant-boost technique, a total dose of 54 Gy is given to the primary tumor. This dose is at least 10% higher than that conventionally used in the currently accepted protocols for neoadjuvant irradiation of rectal cancer.
2.4. Imaging technique

All patients were examined by MRI at two time points: about 1 week prior to CRT (pre-CRT MRI) and 7 weeks after the end of CRT (post-CRT MRI).

All pre-CRT and post-CRT MRI examinations were performed with a closed-configuration superconducting 1.5-T system (Signa HDxT; GE Healthcare, Milwaukee, Wis) with 57.2 mT/m gradient strength and 120 T/m/s slew rate, by using an eight-channel high-resolution torso coil with array spatial sensitivity technique (ASSET) parallel acquisition. Informed consent of MRI examination was obtained from all patients at the time of scanning after the nature and contraindications of the procedure were fully explained.

About three hours before the MR study, the patients performed a rectal cleansing with a water enema.

Table 1 summarizes our MR imaging protocol.

2.5. Image analysis

The evaluation of MR examinations was performed by two radiologists (a senior radiologist with 7 years of clinical experience in body MRI and a junior radiologist with 1 year of practice experience) who were blinded to information obtained at surgery and pathologic analysis.

Qualitative analysis was performed by the two radiologists in consensus. They reviewed the two image sets (the conventional MR image set and the combined set of conventional and DW MR images) in two different reading sessions over an 8-week period. To avoid any recall bias, the order of cases was changed in the second reading session.

First, the radiologists reviewed both the pre-CRT and post-CRT conventional MR images and recorded their confidence level with respect to the ypCR during the first reading session. CR was defined
as an unidentified mass or wall thickening in the post-CRT MR examination. A partial response (PR) to treatment was defined as downstaging, or reduction of at least one level in T or N staging between the baseline pre-CRT MR exam and the post-CRT MR exam. No response to treatment (stable disease SD) was defined as stable disease between the two time points MR examinations.

At the second reading session, the reviewers recorded their confidence level with respect to the ypCR for the combined image set (the conventional MR image set, the pre- and post-CRT DW MR image set and the ADC map). CR was defined as nondepiction of high signal intensity in the corresponding tumor on DW MR images. The presence of residual high signal intensity on DW MR images (low signal intensity on the ADC map) in the corresponding tumor was considered a sign of a PR. SD was defined as stable disease between the two time points MR examinations. When the findings on DW MR images differed from those on conventional MR images, reviewers gave priority to the findings of the former ones.

In the quantitative assessment the measurements of the ADC were performed on both pre-CRT and post-CRT DW MR images by the two radiologists in consensus in a successive session, by using a workstation with diffusion analysis software (Advantage Windows version 4.6, General Electric Medical Systems, Milwaukee, WI, USA). To obtain the ADC measurements the radiologists placed at least three oval regions of interest (ROIs) (mean size 10 mm²; range 8–14 mm²) on the DW images (b = 0, b = 800 s/mm²) on the rectal wall in the area of brightest signal of the clearly visible tumor, resulting in a total of at least 3 subreadings for each lesion. The ROIs were delineated excluding cancer margins, distortion artifacts and macroscopically visible necrotic or cystic portions, and were automatically copied to the corresponding ADC map. T2-weighted
images were observed to assist in correctly identifying the tumor. Following completion of therapy, if there was no residual tumor detectable on post-CRT images, the ROIs were traced on what was considered to be the normal residual rectal wall, as much as possible in the same area used in pre-CRT MR examination. Subsequently, the values of all subreadings of each time point examination were averaged and the mean ADC value was calculated for each lesion.

2.6. Statistical analysis

All data were presented as the mean ± standard deviation. The data were first tested for normality (Shapiro–Wilk’s test) and homoscedasticity (Levene’s test) and then compared by using one- or two-way analyses of variance (ANOVA)s followed by post hoc multiple comparisons by using Duncan’s test. In particular, the two-way ANOVA was performed by applying the mixed model for independent variables (ypCR, ypPR, and ypSD groups) and repeated measures (ADC pre-CRT and ADC post-CRT examination). The one-way ANOVA was performed on difference between ADC post and ADC pre (∆ ADC post—ADC pre) of the three groups (ypCR, ypPR, ypSD).

Analyses were performed by using Statistica 7.0 for Windows and the significance level was established at p ≤ 0.05.

Diagnostic capabilities of the two image sets (the conventional MR image set and the combined set of conventional and DW MR images) for the diagnosis of CR compared with the reference standard were assessed by measuring accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).

| Table 2 | Statistical analysis. Diagnostic capabilities of the two image sets (the conventional MR image set and the combined set of conventional and DW MR images) for the diagnosis of complete response compared with the reference standard. |
|---------|----------------------------------------------------------------------------------|
|         | T2                                                                 | T2 + DWI       |
| Accuracy% | 87.9                                                                  | 97            |
| Sensitivity% | 20 (15.1–55.1)              | 80 (44.9–151.1) |
| Specificity% | 100                                                                              | 100       |
| PPV%      | 100                                                                              | 100       |
| NPV%      | 87.5                                                                             | 96.6       |

PPV: positive predictive value; NPV: negative predictive value; DWI: diffusion weighted imaging.

* Confidence interval limits.

Cases in which disease was understaged were considered as false negative, cases in which disease was overstaged were considered as false positive.

Receiver-operating characteristics (ROC) analysis with the area under the curve (AUC) was employed to investigate the discriminatory capability for ypCR, responders (ypCR, ypPR) and ypSD of each repeated measure (ADC pre-CRT, ADC post-CRT and ∆ ADC post—ADC pre). For calculation of the sensitivity and specificity the optimal threshold was determined by giving equal weighting to sensitivity and specificity on the ROC curve [17]. Therefore, for each repeated measure we calculated AUC for the following independent variables:

- ypCR versus ypPR and ypSD,
- responders (ypCR, ypPR) versus ypSD,
- ypSD versus responders (ypCR, ypPR).

We used 95% confidence intervals to express the statistical precision of the results. The above mentioned analysis was performed by using MedCalc software for Windows (MedCalc Software version 9.6.4.0, Mariakerke, Belgium).

3. Results

3.1. Patient demographics

31 patients met the above mentioned study criteria and were enrolled in the study (21 men and 10 women, mean age of 65 years with a range of 41–84 years).

The average interval between pre-CRT MR imaging for tumor staging and the start of the treatment was 8 days (range, 4–11 days). The average interval between the completion of CRT and post-CRT MR imaging for response evaluation was 51 days (range, 43–57 days). The average interval between post-CRT MR imaging and surgery was 9 days (range, 5–27 days).

Tumor location was as follows: anal canal, within 4.0 cm of the anal verge (n = 7); distal rectum, within 4.1–8.0 cm of the anal verge (n = 15); middle rectum, within 8.1–12.0 cm of the anal verge (n = 5); proximal rectum, within 12.1–16.0 cm of the anal verge (n = 4).
Table 3 Overall ADC value of rectal cancer and mean ADC value of ypCR, ypPR and ypSD groups at each time point (means ± standard deviation).

| Group      | ADC pre-CRT (× 10⁻³ mm²/s) | ADC post-CRT (× 10⁻³ mm²/s) | ∆ ADC post–ADC pre (× 10⁻³ mm²/s) |
|------------|-----------------------------|-----------------------------|----------------------------------|
| overall ADC| 0.85 ± 0.09                 | 1.13 ± 0.18                 | 0.28 ± 0.21                      |
| ypCR       | 0.78 ± 0.05                 | 1.28 ± 0.21                 | 0.51 ± 0.18                      |
| ypPR       | 0.84 ± 0.07                 | 1.16 ± 0.16                 | 0.31 ± 0.19                      |
| ypSD       | 0.91 ± 0.12                 | 1.01 ± 0.14                 | 0.11 ± 0.09                      |

ypCR: complete response; ypPR: partial response; ypSD: stable disease; CRT: chemo-radiotherapy.

Table 4 Statistical analysis. ROC curve analysis.

| ADC pre-CRT | OCV ADC (× 10⁻³ mm²/s) | AUC | Sensitivity% | Specificity% | yPCR vs ypPR and ypSD | responders (ypCR, ypPR) vs ypSD | ypSD vs responders (ypCR, ypPR) |
|-------------|-------------------------|-----|--------------|--------------|-----------------------|---------------------------------|---------------------------------|
|             | 0.8                     | 0.793 | 100          | 66.67        | 0.8                   | 0.718                           | 0.873                           |
| ADC post-CRT| 1.3                     | 0.763 | 60           | 92.59        | 1.1                   | 0.77                           | 1.1                             |
|             | 0.3                     | 0.87 | 100          | 70           | 0.2                   | 0.873                           | 0.873                           |
| ∆ ADC post–ADC pre | 0.3          | 0.87 | 100          | 70           | 0.2                   | 0.873                           | 0.873                           |

ypCR: complete response; ypPR: partial response; ypSD: stable disease; CRT: chemo-radiotherapy; OCV ADC: optimal cut-off ADC value; AUC: area under the ROC curve.

All patients underwent surgical excision: low/ultralow anterior resection (n = 26) and abdominoperineal resection (n = 5); 18/31 patients underwent also temporary diverting loop ileostomy.

At pathological evaluation tumor response was as follows:

– complete response (ypCR) 5/31 patients (16.1%) (Fig. 2);
– partial response (ypPR) 16/31 patients (51.6%) (Fig. 3);
– stable disease (ypSD) 10/31 patients (32.3%) (Fig. 4).

3.2. Qualitative analysis

In the evaluation of CR, the diagnostic performance of the second reading session (combined set of conventional and DW MR images) was better than that of the first one (conventional MR image set) (Table 2). Additional DW MR image interpretation allowed to correct diagnostic errors made on the basis of conventional MR image interpretation alone (n = 3).

3.3. Quantitative analysis

Table 3 shows the overall ADC value of rectal cancer and the mean ADC value of ypCR, ypPR and ypSD groups at each time point.

The overall ADC value of rectal cancer in the pre-CRT examination was significantly lower than that in the post-CRT examination, as revealed by the examination effect of the two-way ANOVA (F1, 28 = 88.63; p < 0.00001) (ADC pre-CRT: 0.85 ± 0.09 × 10⁻³ mm²/s; ADC post-CRT: 1.13 ± 0.18 × 10⁻³ mm²/s).

In the ypCR and ypPR groups, the ADC value of rectal cancer in the pre-CRT examination was significantly lower than that in the post-CRT examination, whereas in the ypSD group the difference was not statistically significant, as revealed by post hoc comparisons on interaction of the two-way ANOVA (F2, 28 = 10.77; p = 0.00003) (post hoc comparisons: ypCR group, p = 0.00002; ypPR group, p = 0.00006; ypSD group, p = 0.07).

Moreover, as revealed by post hoc comparisons on interaction of the two-way ANOVA (F2, 28 = 10.77; p = 0.00003), in the pre-CRT examination the ADC value of rectal cancer of ypCR group was significantly lower than that of ypSD group (p = 0.04); whereas no statistically significant difference was found between ADC value of rectal cancer of ypCR and ypPR groups (p = 0.2) and between ypPR and ypSD groups (p = 0.3). In the post-CRT examination the ADC values of rectal cancer were significantly different among the three groups of tumor response (ypCR vs. ypPR: p = 0.03; ypCR vs. ypSD: p = 0.0001; ypPR vs. ypSD: p = 0.01).

The ∆ ADC post–ADC pre were significantly different among the three groups of tumor response, as revealed by post hoc comparisons of the one-way ANOVA (F2, 28 = 10.77; p = 0.00003) (post hoc comparisons: ypCR vs. ypPR: p = 0.02; ypCR vs. ypSD: p = 0.00001; ypPR vs. ypSD: p = 0.02).

The results of ROC curve analysis are shown in Table 4. The ∆ ADC post–ADC pre showed the best diagnostic capability in identifying both ypCR and responders (ypCR, ypPR). In particular, when an ADC > 0.3 (× 10⁻³ mm²/s) was used as the cut-off value for distinguishing between the ypCR and ypPR-ypSD groups [area under the ROC curve (AUC), 0.87], a sensitivity of 100% and a specificity of 70.37% were obtained. When an ADC > 0.2 (× 10⁻³ mm²/s) was used as the cut-off value for distinguishing between the responders (ypCR, ypPR) and ypSD groups [area under the ROC curve (AUC), 0.873], a sensitivity of 72.73% and a specificity of 100% were obtained.

4. Discussion

In this study we evaluated the diagnostic value of qualitative and quantitative DWI findings in the assessment of tumor response to neoadjuvant CRT in patients with locally advanced rectal cancer.

Our study demonstrated that:

– the addition of DWI sequence’s qualitative assessment to conventional high-resolution T2-weighted sequences improves the diagnostic performance of MRI in the evaluation of ypCR (sensitivity 80%, specificity 100%);
– in the ypCR group the ADC value of rectal cancer in the per-CRT examination was significantly lower than that in the post-CRT examination; in the pre-CRT examination the ADC value of ypCR group was significantly lower than that of ypSD group;
Δ ADC post–ADC pre (sensitivity 100%, specificity 70.37%) yields better diagnostic capability than ADC pre–CRT (sensitivity 100%, specificity 66.67%) and ADC post–CRT (sensitivity 60%, specificity 92.59%) in the evaluation of ypCR.

In our case series tumor response rate after CRT was 67.7%, in particular 16.1% of patients showed a complete tumor response and 51.6% a partial response. These data are substantially in line with those from scientific literature in which complete response rate ranges from 15% to 27% and partial response rate from 54% to 75% [3].

The first of our purposes was to investigate the added value of qualitative DW MRI evaluation in rectal cancer response assessment after neoadjuvant CRT.

Our results showed that in the evaluation of ypCR the diagnostic performance of the combined set of conventional and DW MR images was better than that of the conventional MR image set. Sensitivity improved from 20% to 80%, NPV from 87.5% to 96.6% and accuracy from 87.9% to 99.6%. In 3 cases the interpretation of additional DW MR images allowed us to correct diagnostic errors made on the basis of conventional MR image interpretation alone, differentiating viable tumor from fibrosis.

Our results are consistent with those of previous studies on rectal cancer [8,18–20] in which adding DWI to conventional MR sequences was helpful for detecting viable tumor after neoadjuvant CRT. In a recently published systematic review Joye et al. [6] found that late qualitative DWI assessment can predict ypCR with a pooled specificity of 94% and an overall accuracy of 87%, thereby outperforming quantitative DWI measurements.

The second of our purposes was to evaluate the diagnostic performance of rectal cancer’s ADC measurements for the assessment of therapeutic response to CRT.

In our case series the overall ADC value of rectal cancer in the pre–CRT examination was significantly lower than that in the post–CRT examination. In the ypCR and ypPR groups, the ADC value in the pre–CRT examination was significantly lower than that in the post–CRT examination, whereas in the ypSD group the difference was not statistically significant.

Moreover, in the pre–CRT examination the ADC value of rectal cancer of ypCR group was significantly lower than that of ypSD group (p = 0.04); though no statistically significant difference was found between ADC value of rectal cancer of ypCR and ypPR groups (p = 0.2) and between ypPR and ypSD groups (p = 0.3).

In the post–CRT examination the ADC value of the ypCR group was significantly higher than that of ypPR and ypSD group. Similarly, the Δ ADC post–ADC pre were significantly different among the three groups of tumor response, being higher in the ypCR group.

Concerning the role of rectal cancer’s ADC value in predicting treatment outcomes our data largely confirm earlier reports. Dzik-Jurazs et al. found a negative correlation between the pretreatment tumor ADC value and the percentage shrinkage of the tumor after CRT in rectal cancer. DW MR imaging was effective for the pretreatment prediction of treatment outcome, since patients who responded to treatment had a lower ADC at presentation than those who did not respond [21]. Likewise, the association between high tumor ADC and poor response was consistent with the known relationship between necrosis and poor response to cancer treatment.

As for ROC curve analysis we found that among the three ADC measures (ADC pre–CRT, ADC post–CRT and Δ ADC post–ADC pre), the Δ ADC post–ADC pre showed the best diagnostic capability in identifying ypCR. In particular, when an ADC > 0.3 (×10−3 mm2/s) was used as the cut-off value for distinguishing between the ypCR and ypPR–ypSD groups [area under the ROC curve (AUC), 0.87], a sensitivity of 100% and a specificity of 70.37% were obtained.

Our results are very similar to those obtained by Kim et al. [22] that found the percentage of the ADC increase (cut-off value of 42%) to be an useful predictor for ypCR with a sensitivity of 100% and a specificity of 71%. Similarly, Lee et al. [23] reported that the percentage change in ADC was significantly correlated with pathological response.

Conversely in the study of Semedo et al. [4] Δ ADC post–ADC pre was not reliable in predicting ypCR (sensitivity of 54% and specificity of 64%).

Such a discrepancy between the results of the different studies can be explained by several factors; among these the definition of responder group (ypCR or downstaging) seems to be the most relevant. However, the ypCR, which was used in our as in other studies, is a more objective reference standard than tumor volume reduction rate. The variability depending on coil systems, scanners, magnetic field strength and MR imaging protocol (different b values), along with study population and design, different ADC measurement methods, interobserver variability and operator dependence on ROI positioning should also be considered.

In their systematic review, Joye et al. [6] collected the current evidence on the role of DWI in the prediction of ypCR before, during and after CRT for rectal cancer. They found the following data: a low pretreatment ADC, the change in ADC after 10–15 fractions of radiation therapy (ΔADCduring) and a high ADCpost value were significantly correlated with ypCR.

Consistent with this previous report, our results confirm the potential of pre–CRT examination ADC value to predict treatment response even before the start of therapy and the assumption that the change in ADC values (Δ ADC post–ADC pre) has the potential to provide a surrogate biomarker of treatment response in rectal cancer.

Nevertheless, as demonstrated by previous Authors [6], no technique alone is accurate enough to safely select patients with ypCR; indeed, in our study, although a specificity of 100%, qualitative DWI analysis showed a sensitivity of 80% and quantitative ADC assessment, despite a sensitivity of 100%, yielded a specificity of 70%.

The present study has some limitations. The first limitation is due to its retrospective design which may predispose to selection bias. Second, we used 2 b-values (0 and 800 s/mm2) for ADC calculations and did not investigate the possible influence of other b-values. Third, our study lacks an early follow-up MR examination that could allow an earlier and accurate prediction of the pathological tumor response during CRT treatment, thus enabling to guide modifications of the treatment protocol [24].

5. Conclusions

In our series, use of qualitative DW MR imaging assessment in addition to conventional MR imaging yielded better diagnostic accuracy in the evaluation of ypCR to neoadjuvant CRT in patients with locally advanced rectal cancer.

A low tumor ADC value in the pre–CRT examination, a high ADC value in the post–CRT examination, a high Δ ADC post–ADC pre (>0.3 (×10−3 mm2/s)) were predictive of ypCR.

Nevertheless, although DW sequences improve MR capability to evaluate tumor response to CRT, no functional MR technique alone seems accurate enough to safely select patients with ypCR. Therefore, only a multidisciplinary approach based on the combination of morphological techniques (high-resolution T2-weighted sequences), different functional imaging modalities (qualitative and quantitative DWI), endoscopic findings, clinical data and laboratory parameters might allow to reach a sufficient diagnostic accuracy to select patients candidate for organ-sparing strategies.

The contribution of DW MRI in the study of rectal cancer needs further evaluation in a larger study cohort and prospective, multicenter trials are necessary to fully evaluate the impact of functional
MRI on clinical decision making (surgery, conservative treatment or “wait and watch” approach).

Conflicts of interest

None.

All authors disclose any financial and personal relationships with other people or organizations that could inappropriately influence their work.

References

[1] A. Maier, M. Fuchsjaeger, Preoperative staging of rectal cancer, Eur. J. Radiol. 47 (2003) 89–97.
[2] U.J. Attenberger, L.R. Pilz, J.N. Morelli, D. Hausmann, F. Deyon, R. Hofheinz, P. Kienle, S. Post, H.J. Michaela, S.O. Schoenberg, D.J. Dinter, Multi-parametric MRI of rectal cancer—do quantitative functional MR measurements correlate with radiologic and pathologic tumor stages? Eur. J. Radiol. 83 (2014) 1036–1043, http://dx.doi.org/10.1016/j.ejrad.2014.03.012.
[3] M. Maas, P.J. Nelemans, V. Valentini, et al., Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data, Lancet Oncol. 11 (2010) 835–844.
[4] L.C. Semedo, D.M. Lambregts, M. Maas, et al., Rectal cancer: assessment of complete response to preoperative combined radiation therapy with chemotherapy conventional MR volumetry versus diffusion-weighted MRI imaging, Radiology 260 (2011) 734–741.
[5] E. Kluza, E.D. Rozeboom, M. Maas, M. Martens, D.M. Lambregts, J. Slenter, G.L. Beets, R.G. Beets-Tan, T2 weighted signal intensity evolution may predict pathological complete response after treatment for rectal cancer, Eur. Radiol. 23 (2013) 253–261, http://dx.doi.org/10.1007/s00330-012-2578-z.
[6] J. Joyce, C.M. Deroose, V. Vandecaveye, K. Haustermans, The role of diffusion-weighted MRI and (18F)-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review, Radiother. Oncol. 113 (2014) 158–165, http://dx.doi.org/10.1016/j.radonc.2014.11.026.
[7] S.D. Allen, A.R. Padhani, A.S. Dzik-Jurasz, R. Glynn-Jones, Rectal carcinoma: MRI with histologic correlation before and after chemoradiation therapy, AJR Am. J. Roentgenol 188 (2007) 442–451.
[8] S.H. Kim, J.M. Lee, S.H. Hong, G.H. Kim, J.Y. Lee, J.K. Han, B.J. Choi, Locally advanced rectal cancer: added value of diffusion-weighted MR imaging in the evaluation of tumor response to neoadjuvant chemoradiation therapy, Radiology 253 (2009) 116–125, http://dx.doi.org/10.1148/radiol.2530900207.
[9] L. Monguzzi, D. Ippolito, D.P. Bernasconi, C. Trattenero, S. Galimberti, T. Sironi, Locally advanced rectal cancer: value of ADC mapping in prediction of tumor response to radiochemotherapy, Eur. J. Radiol. 82 (2013) 234–240, http://dx.doi.org/10.1016/j.ejrad.2012.09.027.
[10] D.J. Kim, J.H. Kim, J.S. Lim, J.S. Yu, J.J. Chung, M.J. Kim, K.W. Kim, Restaging of rectal cancer with MR imaging after concurrent chemoradiotherapy and radiation therapy, Radiographics 30 (2010) 503–516, http://dx.doi.org/10.1148/radiographics.302095046.
[11] B. Barbaro, R. Vitale, I. Leccisotti, F.M. Vecchio, L. Santoro, V. Valentini, C. Coco, F. Pacelli, A. Crucitti, R. Persiani, I. Bonomo, Restaging locally advanced rectal cancer with MR imaging after chemoradiation therapy, Radiographics 30 (2010) 699–716, http://dx.doi.org/10.1148/rg.303095085.
[12] L. Curvo-Senedo, D.M. Lambregts, M. Maas, G.L. Beets, F. Caseiro-Alves, R.G. Beets-Tan, Diffusion-weighted MRI in rectal cancer: apparent diffusion coefficient as a potential noninvasive marker of tumor aggressiveness, J. Magn. Reson. Imaging 35 (2012) 1365–1371.
[13] Lu Zhi-hua, Hu Chun-hong, Qian Wei-xin, Cao Wen-hong, Preoperative diffusion-weighted imaging value of rectal cancer: preoperative T staging and correlations with histological T stage, J. Clin. Imaging (2015), http://dx.doi.org/10.1016/j.jcin.2015.12.006.
[14] D.M. Koh, D.J. Collins, Diffusion-weighted MRI in the body: applications and challenges in oncology, AJR Am. J. Roentgenol. 187 (2007) 1622–1635.
[15] E. Neri, E. Guidi, F. Pancrazi, M. Castagna, E. Castelluccio, R. Balestri, P. Bucchiati, L. Masi, A. Falcone, B. Manfredi, L. Faggioni, C. Bartolozzi, MRI tumor volume reduction rate vs tumor regression grade in the pre-operative re-staging of locally advanced rectal cancer after chemoradiotherapy, Eur. J. Radiol. 84 (2015) 2438–2443, http://dx.doi.org/10.1016/j.ejrad.2015.08.008.
[16] S.F. Carbone, L. Pirtoli, V. Ricci, D. Venezia, T. Carfagni, S. Laizi, V. Mourmouras, B. Lorenzi, L. Volterrani, Assessment of response to chemoradiation therapy in rectal cancer using MR volumetry based on diffusion-weighted data sets: a preliminary report, Radiol. Med. 117 (2012) 112–1124, http://dx.doi.org/10.1007/s11547-012-0829-2.
[17] M. Lambrecht, C. Deroose, S. Roels, V. Vandecaveye, F. Penninckx, X. Sagaert, E. van Cutsem, F. de Keyzer, K. Haustermans, The use of FDG-PET/CT and diffusion-weighted magnetic resonance imaging for response prediction before, during and after preoperative chemoradiotherapy for rectal cancer, Acta Oncol. 49 (2010) 956–963, http://dx.doi.org/10.3109/02841860903498439.
[18] S. Sassen, M. de Booij, S. Sosef, et al., Locally advanced rectal cancer: is diffusion weighted MRI helpful for the identification of complete responders (ypT0N0) after neoadjuvant chemoradiation therapy? Eur. Radiol. 23 (2013) 3440–3449.
[19] D.M. Lambregts, V. Vandecaveye, B. Barbaro, et al., Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study, Ann. Surg. Oncol. 18 (2011) 2224–2231.
[20] J. Song, S.H. Kim, S.J. Lee, J.Y. Choi, M.J. Kim, H. Rhim, Value of diffusion-weighted imaging in the detection of viable tumour after neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer: comparison with T2 weighted and PET/CT imaging, Br. J. Radiol. 85 (2012) 577–586.
[21] A. Dzik-Jurasz, C. Domeng, M. George, et al., Diffusion MRI for prediction of response of rectal cancer to chemoradiation, Lancet 360 (2002) 307–308.
[22] S.H. Kim, J.Y. Lee, J.M. Lee, J.K. Han, B.J. Choi, Apparent diffusion coefficient for evaluating tumour response to neoadjuvant chemoradiation therapy for locally advanced rectal cancer, Eur. Radiol. 21 (2011) 987–995.
[23] E.M. Lee, Y.S. Hong, K.P. Kim, et al., Phase II study of preoperative chemoradiation with 5–1 oxaliplatin in patients with locally advanced rectal cancer, Cancer Sci. 104 (2013) 111–115.
[24] D. Musio, F. De Felice, A.L. Magnante, M. Ciolina, C.N. De Cecco, M. Rengo, A. Redler, A. Laghi, N. Raffetto, V. Tombolini, Diffusion-weighted magnetic resonance application in response prediction before, during, and after neoadjuvant radiochemotherapy in primary rectal cancer carcinoma, Biomed. Res. Int. 2013 (2013) 740195, http://dx.doi.org/10.1155/2013/740195.